Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants

• Status: Completed
• Trial end date: 2004-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this trial is to study the effect of adding the omega-3 fatty acid EPA and/or Vitamins E + C to antipsychotic drugs in younger patients with schizophrenia and related psychoses.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University Hospital, Aker
• Collaborators: AstraZeneca; Diakonhjemmet Hospital; Johanne and Einar Eilertsen's research fund; Josef and Haldis Andresen's legacy; Laxdale Ltd; Norwegian University of Science and Technology; Scandinavian Society for Psychopharmacology; Shipowner Emil Stray's legacy; Solveig and Johan P. Sommer's foundation; Stanley Medical Research Institute; University of Oslo
• Treatments: alpha-Tocopherol; Antioxidants; Ascorbic Acid; Eicosapentaenoic acid ethyl ester; Tocopherols; Tocotrienols; Vitamin E; Vitamins

Criteria

Inclusion Criteria:

• Patients with schizophrenia, schizophreniform disorder or schizoaffective disorder (DSM-IV)

• Admitted to a psychiatric hospital/department within the previous twenty-one days before screening

• Less than fifteen years, in retrospect, since first psychotic symptoms (DSM-IV 295, criteria A,1-4)

• Age 18-40 years

• Speaks fluently a Scandinavian language

• A written informed consent must be obtained before any trial-related activities

Exclusion Criteria:

• A diagnosis of substance dependence (DSM-IV)

• Known allergy to study medication

• Currently taking warfarin or having anamnestic indicators of impaired haemostasis (profuse bleeding, except epistaxis)